ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Re...
April 09 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the
Company’s orally-administered small molecule PD-L1 inhibitor,
CCX559, will be featured in a poster presentation at the virtual
2021 Annual Meeting of the American Association for Cancer Research
(AACR). The poster presentation, which showcases CCX559’s ability
to induce anti-tumor immunity, will go live on Saturday, April 10
at 8:30 a.m. ET as part of the Novel Antitumor Agents Session
(PO.ET06.03).
PD-L1/PD-1 interaction is one of the major checkpoints that
limit effector T cell function against cancer cells. As a next
generation therapy, small molecule inhibitors of PD-L1 may have
advantageous properties compared to approved monoclonal antibodies,
such as better penetration into solid tumors, reduced
immunogenicity, lack of Fc-mediated side effects, convenience of
oral administration, and lower cost of goods.
The study featured in the AACR poster presentation demonstrated
that CCX559 potentially employs distinct mechanisms to inhibit
PD-L1 compared to the anti-human PD-L1 antibodies. In murine tumor
models, orally administered CCX559 reduced tumor growth similarly
to a clinically-approved anti-human PD-L1 antibody.
Based on CCX559’s unique mechanism of PD-L1 inhibition, strong
anti-tumor activity, desirable drug properties, and good safety
profile, the Company plans to advance CCX559 into clinical
development in the first half of 2021.
About ChemoCentryxChemoCentryx is a
biopharmaceutical company developing new medications for
inflammatory and autoimmune diseases and cancer. ChemoCentryx
targets the chemokine and chemoattractant systems to discover,
develop and commercialize orally-administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 Glomerulopathy (C3G).
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other inflammatory and autoimmune
diseases and in cancer.
Forward-Looking StatementsChemoCentryx cautions
that statements included in this press release that are not a
description of historical facts are forward-looking statements.
Words such as "may," "could," "will," "would," "should," "expect,"
"plan," "anticipate," "believe," "estimate," "intend," "predict,"
"seek," "contemplate," "potential," "continue" or "project" or the
negative of these terms or other comparable terminology are
intended to identify forward-looking statements. These statements
include the Company's statements regarding the timing of advancing
CCX559 into clinical development, whether CCX559 will demonstrate
advantageous properties compared to monoclonal antibodies and
whether CCX559 will be shown to be safe and effective in ongoing or
future clinical trials. The inclusion of forward-looking statements
should not be regarded as a representation by ChemoCentryx that any
of its plans will be achieved. Actual results may differ from those
set forth in this release due to the risks and uncertainties
inherent in the ChemoCentryx business and other risks described in
the Company's filings with the Securities and Exchange Commission
("SEC"). Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and ChemoCentryx undertakes no obligation to revise or
update this news release to reflect events or circumstances after
the date hereof. Further information regarding these and other
risks is included under the heading "Risk Factors" in
ChemoCentryx's periodic reports filed with the SEC, including
ChemoCentryx's Annual Report on Form 10-K filed with the SEC on
March 1, 2021 and its other reports which are available from the
SEC's website (www.sec.gov) and on ChemoCentryx's website
(www.chemocentryx.com) under the heading "Investors." All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
Contacts:Susan M. KanayaExecutive Vice
President,Chief Financial and Administrative
Officerinvestor@chemocentryx.com
Media:Stephanie
Tomei408.234.1279media@chemocentryx.com
Investors:Burns McClellan, Inc.Lee
Roth212.213.0006lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024